DealForma @DealForma

The deal and funding database built for biopharma. Curated deal comps, company profiles, pipelines, dedicated analyst support so you do better research faster dealforma.com San Mateo, CA Joined January 2017

Tweets

349
Followers

416
Following

253
Likes

100

DealForma @DealForma

5 days ago

Cancer remains the most active and competitive therapeutic area, with capital prioritizing late-stage partnerships, transformative acquisitions, and early-stage innovation in modalities such as RNA, cell therapies, and next-generation antibodies. hubs.ly/Q03GxPPk0

0 0 0 67 0

DealForma @DealForma

2 weeks ago

Gene therapy in H1 2025 remained robust across hematology, neurology, rare diseases, oncology, and ophthalmology, with momentum led by late-stage assets, novel capsids, and LNP delivery platforms. Check out our research hubs.ly/Q03FCDbg0

0 0 0 55 0

DealForma @DealForma

2 weeks ago

H1 2025 autoimmune dealmaking remained strong, led by biologics and boosted by AI-driven discovery, multi-target platforms, and targeted delivery, with large pharma focusing on late-stage assets via selective M&A and milestone-heavy partnerships. hubs.ly/Q03F2Rc-0

0 0 0 53 0

DealForma @DealForma

4 weeks ago

Q2 2025 marked a strong yet selective quarter for biopharma financing, with six major companies raising over $3 billion across IPOs and PIPEs. Check out our research hubs.ly/Q03CnGJZ0

0 0 0 53 0

DealForma @DealForma

a month ago

Excited to share that J.P. Morgan’s latest Biopharma & Medtech Deal Reports are now live — powered by DealForma data. It's been an incredible 5+ years working with the J.P. Morgan Life Sciences team! hubs.ly/Q03BHfT-0

0 2 6 5K 5

DealForma @DealForma

a month ago

Did you know that DealForma now includes unredacted contracts as part of our licensing, M&A, and supply deal coverage? You’ll see these unredacted documents linked directly from deal profiles where available - free to all DealForma customers.

0 0 0 74 0

Download Image

DealForma @DealForma

a month ago

Our Q2 2025 review of biopharma venture funding reflected a clear flight to quality, with capital concentrating on clinically validated platforms and de-risked science. Check out our research hubs.ly/Q03Bbth00

0 0 0 51 0

DealForma @DealForma

a month ago

The Q2 2025 biopharma M&A landscape marked a strategic pivot toward targeted, mid-sized acquisitions, following a high-volume Q1. Check out our research hubs.ly/Q03zlC5g0

0 0 0 51 0

DealForma @DealForma

2 months ago

If you missed John Knox's MedTech Summit, Chris Dokomajilar, CEO and Founder of DealForma presented the latest charts from the DealForma database tracking venture investments, licensing partnerships, and M&A in the medtech space. You can it at 2:47 mark. hubs.ly/Q03x6Lcb0

0 0 0 59 0

Download Image

DealForma @DealForma

2 months ago

Biotech dealmaking stayed strong in H1 2025 despite a tough market — M&A and AI-driven deals helped offset a dip in licensing. New charts via Dealforma in this Endpoints piece. hubs.ly/Q03w-66v0

0 0 0 63 1

Download Image

DealForma @DealForma

2 months ago

The Endpoints article highlights how biotech dealmaking has remained resilient in 2025 despite a tough fundraising climate, with a notable surge in licensing, M&A, and AI-driven agreements keeping activity high. Read it here hubs.ly/Q03wZFx40

0 0 1 83 0

DealForma @DealForma

2 months ago

The first half of 2025 saw robust activity in the autoimmune space, with high-value R&D partnerships, strategic M&A deals, and strong venture funding. Check out our research hubs.ly/Q03wyCKj0

0 0 1 40 0

DealForma @DealForma

2 months ago

Biopharma licensing brought in $10 billion upfront in H1 2025. $7.7 billion of this was from 18 deals that had more than $100M upfront to challenge full-year 2024.

0 0 1 83 0

Download Image

DealForma @DealForma

2 months ago

M&A bankers had the busiest year in a while. Here's a look at H1 2025 M&A when we zoom out the database to broader life sciences, medtech, and CDMOs.

0 0 1 96 0

Download Image

DealForma @DealForma

2 months ago

Your first look at biopharma-to-biopharma M&A through Q2. Capstan/AbbVie bumped up the median upfront M&A value. DealForma customers get reports full of charts on licensing and funding activity in Q2. Contact me if you are interested

0 0 0 94 0

Download Image

DealForma @DealForma

3 months ago

Nature’s article on biotech’s shifting landscape cites DealForma data showing 2025 venture financing nearing $27B, with more money going to fewer, well-funded startups. Read it here hubs.ly/Q03sPS4y0

0 0 0 49 0

DealForma @DealForma

3 months ago

Cancer activity by TA was strong in Q1 2025, with significant R&D partnerships, acquisitions, and venture investments signaling continued growth. Read our research. hubs.ly/Q03s2kN70

0 0 1 39 0

DealForma @DealForma

3 months ago

Stifel’s ASCO 2025 recap, with DealForma data, highlights ADCs, bispecifics, evolving buyer strategies, and China’s rise in oncology licensing. Read it here hubs.ly/Q03r8Ls20

0 0 0 37 0

DealForma @DealForma

3 months ago

Our Q1 2025 review shows strong M&A and funding momentum across MedTech, especially in cardio, ortho, diabetes, ophthalmology, and digital health. Check out our research hubs.ly/Q03qWgSW0

0 0 0 36 0

DealForma @DealForma

3 months ago

AI drug discovery deals now feature nine‑figure upfronts and billion‑dollar milestones, with DealForma data showing a shift toward biologics, real‑world data, and broader pharma-AI partnerships. Read Nature's article here. hubs.ly/Q03qWg8q0